Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GM-XANTHO in Patients With Psoriasis
NCT06620692Phase 2Not yet recruiting
- Sponsor
- Xantho Biotechnology
- Start
- Oct 2026
- Primary completion
- Dec 2027
- Modality
- Hydrogel Systems, Transdermal Patches
01
Overview
Phase 2, randomised, double-blind trial in psoriasis comparing 5 % GM-XANTHO [GM-XAN003] group with Placebo group (2 arms). Primary endpoint: Psoriasis Area and Severity Index at 7 weeks. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
GM-XANTHO
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT06620692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06620692.